CT引导高剂量率近距离放疗与经动脉化疗栓塞治疗不可切除肝细胞癌患者的比较
这项多机构回顾性研究纳入2010年1月至2022年12月初治的不可切除肝细胞癌成人患者,经倾向性评分匹配后比较CT引导高剂量率近距离放疗与经动脉化疗栓塞的结局。匹配后近距离放疗组与经动脉化疗栓塞组各150例,经动脉化疗栓塞组死亡风险更高(HR 4.04,P < .001),疾病进展风险亦更高(HR 2.23,P < .001)。
要点
- 匹配后经动脉化疗栓塞组死亡风险高于近距离放疗组(HR 4.04,P < .001)。
- 近距离放疗组中位无进展生存期32.8个月,经动脉化疗栓塞组11.6个月。
- 经动脉化疗栓塞组疾病进展风险高于近距离放疗组(HR 2.23,P < .001)。
核心结论
- 在经选择的初治不可切除肝细胞癌患者中,CT引导高剂量率近距离放疗较经动脉化疗栓塞改善了总生存期和无进展生存期。
研究设计与样本
- 多机构回顾性研究,纳入2010年1月至2022年12月初治的不可切除肝细胞癌成人连续患者,比较CT引导高剂量率近距离放疗与经动脉化疗栓塞,采用倾向性评分匹配平衡临床和肿瘤特征。
诊断标准与关键数值
- 匹配后近距离放疗组150例(中位年龄71岁,IQR 63-77岁;男性117例),经动脉化疗栓塞组总生存分析150例(中位年龄70岁,IQR 63-77岁;男性119例)。
- 经动脉化疗栓塞组无进展生存分析中位年龄68岁(IQR 63-76岁),男性119例。
- 风险比由Kaplan-Meier生存曲线计算,经动脉化疗栓塞组较近距离放疗组死亡风险HR 4.04(P < .001),疾病进展风险HR 2.23(P < .001)。
- 近距离放疗组中位估计无进展生存期32.8个月(95% CI:12.5,58.7),经动脉化疗栓塞组11.6个月(95% CI:4.9,22.7)。
局限性
- 本研究为多机构回顾性研究。
- 并非所有接受经动脉化疗栓塞的患者有无进展生存数据可用,故该治疗的无进展生存和总生存分析采用了不同的患者集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background CT-guided high-dose-rate (HDR) brachytherapy (hereafter, HDR brachytherapy) has been shown to be safe and effective for patients with unresectable hepatocellular carcinoma (HCC), but studies comparing this therapy with other local-regional therapies are scarce. Purpose To compare patient outcomes of HDR brachytherapy and transarterial chemoembolization (TACE) in patients with unresectable HCC. Materials and Methods This multi-institutional retrospective study included consecutive treatment-naive adult patients with unresectable HCC who underwent either HDR brachytherapy or TACE between January 2010 and December 2022. Overall survival (OS) and progression-free survival (PFS) were compared between patients matched for clinical and tumor characteristics by propensity score matching. Not all patients who underwent TACE had PFS available; thus, a different set of patients was used for PFS and OS analysis for this treatment. Hazard ratios (HRs) were calculated from Kaplan-Meier survival curves. Results After propensity matching, 150 patients who underwent HDR brachytherapy (median age, 71 years [IQR, 63-77 years]; 117 males) and 150 patients who underwent TACE (OS analysis median age, 70 years [IQR, 63-77 years]; 119 male; PFS analysis median age, 68 years [IQR: 63-76 years]; 119 male) were analyzed. Hazard of death was higher in the TACE versus HDR brachytherapy group (HR, 4.04; P < .001). Median estimated PFS was 32.8 months (95% CI: 12.5, 58.7) in the HDR brachytherapy group and 11.6 months (95% CI: 4.9, 22.7) in the TACE group. Hazard of disease progression was higher in the TACE versus HDR brachytherapy group (HR, 2.23; P < .001). Conclusion In selected treatment-naive patients with unresectable HCC, treatment with CT-guided HDR brachytherapy led to improved OS and PFS compared with TACE. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Chapiro in this issue.
引用
- Auer TA, Müller L, Schulze D, et al. CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma. Radiology. 2024. PMID: 38319166. doi:10.1148/radiol.232044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。